IGC Pharma
Tracked across 2 events · 12 articles · First seen Apr 28, 2026 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: IGC Pharma announced its participation in a caregiver-focused podcast to raise awareness for Alzheimer's disease agitation and support patient engagement in its Phase 2 CALMA clinical trial, which is nearing completion of enrollment. This outreach aims to accelerate the trial's progress and potential future drug development.
Apr 28, 2026 · 6 articles
Business
IGC Pharma, Inc. reported financial results for Q2 2026 and provided an update on its lead Alzheimer's program, IGC-AD1. The Phase 2 CALMA trial reached its 146-patient baseline randomization target and is within six randomizations…
Impact: IGC Pharma is the central entity, reporting Q2 results and advancing its lead Alzheimer's candidate. The trial progress and equity conversion are positive, but financial losses and low cash remain concerns.
Aug 17, 2026 · 6 articles
90
IGC Pharma advanced enrollmentIGC Pharma Q2 2026 CALMA...
50
IGC Pharma converted debt to equity Ram MukundaIGC Pharma Q2 2026 CALMA...
40
IGC Pharma received psilocybin authorization ColombiaIGC Pharma Q2 2026 CALMA...
30
IGC Pharma reported Q2 resultsIGC Pharma Q2 2026 CALMA...
ERGEN INTELLIGENCE
Track IGC Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard